skip to Main Content
MHRA Approve Risdiplam EAMS Application

MHRA approve risdiplam EAMS application

We currently have limited information but we wanted  to get news out to you as soon as possible. The MHRA have approved the use of risdiplam for type 1 and type 2 patients over the age of two months with no upper age limit.

Detail is scant at the moment and we are submitting a number of questions to Roche and will provide as much information as we can as soon as we get it. This is great news for a lot of the SMA community, but we must remember that some are still excluded and we continue to push.

https://www.gov.uk/government/publications/risdiplam-in-the-treatment-of-type-1-and-type-2-spinal-muscular-atrophy-sma-in-patients-2-months-of-age-and-older

Back To Top